{"id":47567,"date":"2022-08-23T13:01:59","date_gmt":"2022-08-23T11:01:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/"},"modified":"2022-08-23T13:01:59","modified_gmt":"2022-08-23T11:01:59","slug":"vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/","title":{"rendered":"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA"},"content":{"rendered":"<div>\n<p>AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;VectorY, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders through vectorized antibodies, announces today that it will present a poster at the Hereditary Disease Foundation 2022 Meeting in Cambridge, Massachusetts, on August 24-27, 2022.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220823005473\/en\/1551025\/4\/VectorY_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220823005473\/en\/1551025\/21\/VectorY_logo.jpg\"><\/a><\/p>\n<p>\nThe poster shows that VectorY\u2019s AAV vector, dose-dependently transduced AAV iPS derived human neurons and astrocytes <i>ex vivo<\/i>, and AAV vector-delivered transgenes were expressed long-term in the brains and spinal cords of mice and pigs. Several VecTab candidates were identified that effectively removed huntingtin aggregates from U2OS cells that expressed a CAG-repeat-expanded pathological form of huntingtin.\n<\/p>\n<p>\nHuntington\u2019s Disease is caused by aggregates of polyglutamine-rich HTT protein, which result from CAG repeat expansions of the Huntingtin gene. VecTabs, which are secreted- or intracellular-antibody fragments that are AAV-vectorized and delivered to neurons and\/or astrocytes, have previously been shown to efficiently target such misfolded proteins (TDP-43) and toxic lipids (oxPL). The poster data shows that the platform is also able to target polyglutamine-rich proteins like HTT, demonstrating the clearance of toxic HTT aggregates.\n<\/p>\n<p>\nThe details of the poster are as follows:\n<\/p>\n<p class=\" bwalignl\">\n<b>Title:<\/b> VecTabs<sup>\u00ae<\/sup>: Targeting misfolded and aggregated proteins with vectorized antibodies for the treatment of ALS and HD\n<\/p>\n<p class=\" bwalignl\">\n<b>Time and date:<\/b> 25 August, 6:30 p.m. &#8211; 10:00 p.m. EDT\n<\/p>\n<p class=\" bwalignl\">\n<b>Location:<\/b> Royal Sonesta Hotel Boston, 40 Edwin Land Boulevard, Cambridge, MA 02142\n<\/p>\n<p>\n<b>Pavlina Konstantinova, Chief Scientific Officer of VectorY, said:<\/b> <i>\u201cThe results <\/i><i>that will be <\/i><i>reported <\/i><i>at the Hereditary Disease Foundation are encouraging signals that<\/i><i> <\/i><i>our VecTab technology <\/i><i>has the potential <\/i><i>to<\/i><i> effectively<\/i><i> <\/i><i>target Huntington\u2019s Disease. Our technology enables <\/i><i>the <\/i><i>specific targeting of <\/i><i>misfolded and aggregated proteins, which have been shown to cause neurodegenerative diseases, whilst maintaining the function of the correctly folded native forms of those proteins.\u201d<\/i>\n<\/p>\n<p>\nThe new data demonstrates the effective removal of huntingtin (HTT) aggregates in a preclinical model. VectorY\u2019s novel platform has demonstrated accelerated removal of toxic HTT proteins intracellularly, where they cause damage to the deep brain motor neurons. The research supports and highlights the therapeutic potential and versatility of VectorY\u2019s VecTab platform technology, which was previously reported in preclinical models of amyotrophic lateral sclerosis.\n<\/p>\n<p>\nMembers of the VectorY team will attend the conference in person and will be available to discuss the poster. To meet the team, please contact <a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;&#116;o&#x3a;&#x69;&#x6e;&#102;&#111;&#64;v&#x65;&#x63;&#x74;&#111;&#114;y&#x74;&#x78;&#x2e;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#105;n&#x66;o&#x40;v&#x65;&#99;&#x74;&#111;&#x72;&#121;t&#x78;&#46;&#x63;o&#x6d;<\/a>.\n<\/p>\n<p class=\"bwalignc\">\n<b>ENDS<\/b>\n<\/p>\n<p>\n<b>Notes to Editors<\/b>\n<\/p>\n<p>\n<b>About VectorY<\/b>\n<\/p>\n<p>\nVectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative and -muscular diseases with high unmet medical need. Founded in October 2020 and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative and -muscular diseases, VectorY&#8217;s synergistic technologies may be applied across a wide range of indications. VectorY\u2019s manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands.\n<\/p>\n<p>\nFor more information, see <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vectorytx.com&amp;esheet=52823251&amp;newsitemid=20220823005473&amp;lan=en-US&amp;anchor=www.vectorytx.com&amp;index=1&amp;md5=d467c7744c1da6c9645e4b1e5899d212\" rel=\"nofollow noopener\" shape=\"rect\">www.vectorytx.com<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nFor further information, please contact:<br \/>\n<br \/><b>VectorY B.V.<\/b><br \/>Alexander Vos, CEO<br \/>\n<br \/>Tel: +31 (20) 226 8020\n<\/p>\n<p>\n<b>Instinctif Partners (media enquiries)<\/b><br \/>Melanie Toyne-Sewell \/ Katie Duffell<br \/>\n<br \/>E-mail: <a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#58;&#86;&#101;&#99;torY&#x40;&#x69;&#x6e;&#x73;&#x74;&#x69;&#110;&#99;&#116;&#105;&#102;&#46;co&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x56;e&#x63;&#116;&#x6f;&#114;&#x59;&#x40;i&#x6e;&#115;&#x74;&#105;&#x6e;&#99;t&#x69;&#102;&#x2e;&#99;&#x6f;&#109;<\/a><br \/>Tel: +44 20 7457 2020\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;VectorY, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders through vectorized antibodies, announces today that it will present a poster at the Hereditary Disease Foundation 2022 Meeting in Cambridge, Massachusetts, on August 24-27, 2022. The poster shows that VectorY\u2019s AAV vector, dose-dependently &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47567","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;VectorY, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders through vectorized antibodies, announces today that it will present a poster at the Hereditary Disease Foundation 2022 Meeting in Cambridge, Massachusetts, on August 24-27, 2022. The poster shows that VectorY\u2019s AAV vector, dose-dependently ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-23T11:01:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220823005473\/en\/1551025\/21\/VectorY_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA\",\"datePublished\":\"2022-08-23T11:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/\"},\"wordCount\":546,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005473\\\/en\\\/1551025\\\/21\\\/VectorY_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/\",\"name\":\"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005473\\\/en\\\/1551025\\\/21\\\/VectorY_logo.jpg\",\"datePublished\":\"2022-08-23T11:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005473\\\/en\\\/1551025\\\/21\\\/VectorY_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005473\\\/en\\\/1551025\\\/21\\\/VectorY_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/","og_locale":"en_US","og_type":"article","og_title":"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA - Pharma Trend","og_description":"AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;VectorY, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders through vectorized antibodies, announces today that it will present a poster at the Hereditary Disease Foundation 2022 Meeting in Cambridge, Massachusetts, on August 24-27, 2022. The poster shows that VectorY\u2019s AAV vector, dose-dependently ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-23T11:01:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220823005473\/en\/1551025\/21\/VectorY_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA","datePublished":"2022-08-23T11:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/"},"wordCount":546,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220823005473\/en\/1551025\/21\/VectorY_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/","url":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/","name":"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220823005473\/en\/1551025\/21\/VectorY_logo.jpg","datePublished":"2022-08-23T11:01:59+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220823005473\/en\/1551025\/21\/VectorY_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220823005473\/en\/1551025\/21\/VectorY_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vectory-to-present-poster-on-huntingtons-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47567"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47567\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}